Is ApoB a better test than LDL cholesterol?

Yes, apoB predicts heart disease risk better than LDL cholesterol, mainly when the two disagree. Whether treating by apoB improves outcomes beyond treating by LDL isn't yet tested.

Who it's for

People whose LDL and triglycerides tell different stories, or those on statins.

What to expect

A modestly sharper read on risk, added to a standard cholesterol panel.

Watch out for

Most people's apoB and LDL agree, so the extra gain is often small.

What guidelines say

The National Lipid Association finds apoB superior to LDL cholesterol for judging risk before and during treatment, and supports measuring it alongside a standard panel2Guideline · 2024Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid AssociationLDL cholesterol and apoB (or non-HDL cholesterol) can disagree in an individual even though they correlate closely across the population; when they do, cardiovascular risk generally follows apoB or non-HDL cholesterol more closely than LDL cholesterol.National Lipid Association. The Canadian Cardiovascular Society prefers apoB or non-HDL cholesterol over LDL when triglycerides exceed 1.5 mmol/L6Guideline · 20212021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.Health behaviour modification, including regular exercise and a heart-healthy diet, remain the cornerstone of cardiovascular disease prevention. These guidelines are intended to provide a platform for meaningful conversation and shared-decision making between patient and care provider, so that individual decisions can…Can J Cardiol. The 2018 US guideline lists apoB of 130 mg/dL or more as a factor favoring a statin in adults 40 to 75 at borderline or intermediate risk1Guideline · 20182018 Guideline on the Management of Blood CholesterolFor adults 40 to 75 without diabetes at intermediate 10-year risk (7.5% to 19.9%), risk-enhancing factors favor starting a statin, and they may favor it at borderline risk (5% to 7.5%). They include a family history of premature heart disease, LDL cholesterol persistently at 160 mg/dL or more, apoB of 130 mg/dL or m…American Heart Association and American College of Cardiology.

What the studies show

• A review of 15 studies (593,354 people) that compared the tests where they disagreed found apoB beat LDL in all 9 comparisons. It also beat non-HDL cholesterol in most studies7Systematic review · 2025 · 593,354 peopleApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk.Discordance analysis provides robust evidence that apoB is a more accurate marker of cardiovascular risk than either LDL-C or non-HDL-C, notwithstanding these variables are highly intercorrelated. Thus, neither LDL-C nor non-HDL-C are adequate clinical surrogates for apoB. Accordingly, apoB should be the primary…J Clin Lipidol.
• A meta-analysismeta-analysis A study that pools the results of several earlier studies into one overall estimate. It is usually the strongest kind of evidence. of 12 studies (233,455 people, 22,950 events) ranked apoB as the strongest risk marker, non-HDL cholesterol in the middle and LDL weakest4Meta-analysis · 2011 · 455 peopleA meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.These results further validate the value of apoB in clinical care.Circ Cardiovasc Qual Outcomes.
• Among statin-treated people, a study of 13,015 followed for a median of 8 years linked high apoB with low LDL to about 49% higher relative riskrelative risk How much more or less likely something is in one group than another, as a ratio. A big relative change can still be a small change for any one person. of heart attack. High LDL with low apoB carried no extra risk11Observational study · 2021Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients.In statin-treated patients, elevated apoB and non-HDL cholesterol, but not LDL cholesterol, are associated with residual risk of all-cause mortality and myocardial infarction. Discordance analysis demonstrates that apoB is a more accurate marker of all-cause mortality risk in statin-treated patients than LDL…J Am Coll Cardiol. These figures compare groups, so one person's gain depends on their starting risk.
• In 389,529 healthy adults followed for about 11 years, only apoB stayed linked to heart attack when compared with non-HDL cholesterol, LDL and triglycerides10Observational study · 2022 · 529 peopleAssociation of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.In this cohort study, risk of MI was best captured by the number of apoB-containing lipoproteins, independent from lipid content (cholesterol or TG) or type of lipoprotein (LDL or TG-rich). This suggests that apoB may be the primary driver of atherosclerosis and that lowering the concentration of all apoB-containing…JAMA Cardiol.
• A study of about 95,000 untreated adults linked apoB above what LDL explains to higher heart disease risk across all LDL levels9Observational study · 2024 · 53,484 peopleExcess Apolipoprotein B and Cardiovascular Risk in Women and Men.Excess apoB (ie, the value of apoB above that contributed by LDL-C levels alone) is associated dose-dependently with an increased risk of MI and ASCVD in women and men. This finding demonstrates that apoB provides important predictive value beyond LDL-C across the entire LDL-C spectrum.J Am Coll Cardiol.
• The picture is not fully uniform. A pooled analysis of 62,154 statin-treated people found apoB and LDL did not differ significantly, and non-HDL cholesterol did slightly better3Meta-analysis · 2012 · 62,154 peopleAssociation of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.Among statin-treated patients, on-treatment levels of LDL-C, non-HDL-C, and apoB were each associated with risk of future major cardiovascular events, but the strength of this association was greater for non-HDL-C than for LDL-C and apoB.JAMA.
• A pooled analysis of 29 trials (332,912 people) found each 10 mg/dL drop in apoB went with about 7% fewer major heart events, in therapies that work through the LDL receptor5Meta-analysis · 2020 · 332,912 peopleAssociation of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials.While both statin and established non-statin therapies (PCSK9 inhibitor and ezetimibe) reduced cardiovascular risk per decrease in apolipoprotein B, interventions which reduce apolipoprotein B independently of LDL-R were not associated with cardiovascular benefit.Eur J Prev Cardiol.

Key studies

What we don't know

• No finished trial shows that guiding treatment by apoB gives better outcomes than guiding by LDL. One such trial in people having stent procedures is planned13Registered trial · 2025Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary InterventionClinicalTrials.gov.
• Non-HDL cholesterol, which needs no extra test, performed close to apoB in some studies3Meta-analysis · 2012 · 62,154 peopleAssociation of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.Among statin-treated patients, on-treatment levels of LDL-C, non-HDL-C, and apoB were each associated with risk of future major cardiovascular events, but the strength of this association was greater for non-HDL-C than for LDL-C and apoB.JAMA,7Systematic review · 2025 · 593,354 peopleApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk.Discordance analysis provides robust evidence that apoB is a more accurate marker of cardiovascular risk than either LDL-C or non-HDL-C, notwithstanding these variables are highly intercorrelated. Thus, neither LDL-C nor non-HDL-C are adequate clinical surrogates for apoB. Accordingly, apoB should be the primary…J Clin Lipidol.